JACC. Cardiovascular imaging最新文献

英文中文

Academic Profile and Gender Representation of Advanced Cardiac Imaging Fellowship Program Directors in the United States 美国高级心脏成像研究员项目主任的学术概况和性别比例。

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.07.016

Vivek Bhat MBBS, Ashish Kumar MD, Ankur Kalra MD, MSc, Nandan Anavekar MBBCh, Lauren A. Baldassarre MD, Roosha Parikh MD, Purvi Parwani MBBS, MPH

引用次数: 0

Timing of Regadenoson-Induced Peak Hyperemia and the Effects on Coronary Flow Reserve 雷加登罗松诱发峰值高血流的时间及对冠状动脉血流储备的影响

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.08.010

Nathan Kattapuram BS, Shahrad Shadman MD, Eric E. Morgan MD, PhD, Charles Benton AS, Stacian Awojoodu DNP, Dong-Yun Kim PhD, Joao Ramos MD, PhD, Ana Barac MD, PhD, W. Patricia Bandettini MD, Peter Kellman PhD, Gaby Weissman MD, Marcus Carlsson MD, PhD

引用次数: 0

Right Ventricular Systolic Strain Reference Ranges Across Contemporary Vendor-Neutral Echocardiography Software in Healthy Patients 健康患者右心室收缩应变参考范围与当代供应商中立超声心动图软件的比较。

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.08.008

Elio Haroun MD, Ankit Agrawal MD, Joseph El Dahdah MD, Tiffany Dong MD, Aro Daniela Arockiam MD, Muhammad Majid MD, Sharmeen Sorathia MD, Richard A. Grimm DO, L. Leonardo Rodriguez MD, Zoran B. Popovic MD, PhD, Brian P. Griffin MD, Tom Kai Ming Wang MBChB, MD

引用次数: 0

Clinical Characteristics and Outcomes of Patients With Takotsubo Syndrome and Left Ventricular Outflow Tract Obstruction 塔克次博综合征和左心室流出道阻塞患者的临床特征和预后。

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.07.015

Davide Di Vece MD, Michele Bellino MD, Angelo Silverio MD, PhD, Serena Migliarino MD, Eduardo Bossone MD, PhD, Fernando Scudiero MD, Giuseppina Novo MD, Matteo Cameli MD, PhD, Olga Vriz MD, Aneta Aleksova MD, Concetta Zito MD, Pasquale Innelli MD, Fausto Rigo MD, Mario Cristiano MD, Jorge Salerno-Uriarte MD, Tiziana Attisano MD, Gennaro Galasso MD, PhD, Guido Parodi MD, PhD, Gianfranco Sinagra MD, Carmine Vecchione MD, PhD, Rodolfo Citro MD, PhD

引用次数: 0

The Complex Relationship Between Risk Factor Exposure and Coronary Epicardial as Well as Microvascular Disease 危险因素暴露与冠状动脉心外膜及微血管疾病的复杂关系

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.09.011

João A.C. Lima MD , Joanne D. Schuijf PhD

引用次数: 0

Lipid-Lowering Medication and Outcomes After Anatomical and Functional Imaging in Suspected Coronary Artery Disease 疑似冠状动脉疾病患者接受解剖和功能成像检查后的降脂药物和疗效。

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.07.009

Teemu Maaniitty MD, PhD , Matias Mäenpää MD , Esa Harjulahti MD , Iida Kujala MD, PhD , Iida Stenström MD, PhD , Wail Nammas MD, PhD , Juhani Knuuti MD, PhD , Antti Saraste MD, PhD

Background

Anatomical and functional imaging identify different phenotypes of coronary artery disease (CAD) that may have implications for lipid-lowering medication (LLM).

Objectives

The aim of this study was to assess the associations between LLM and long-term outcomes after combined anatomical and functional imaging in patients with suspected obstructive CAD.

Methods

Consecutive patients (n = 1,973; 41% men; median age: 63 years) underwent coronary computed tomography angiography (CTA) because of suspected CAD. Patients in whom obstructive CAD was not ruled out by CTA underwent ischemia testing by positron emission tomography. Data on LLM purchases were collected until 2 years, and the combined endpoints of death, myocardial infarction, and unstable angina pectoris were assessed at a median of 6.7 years.

Results

After imaging, LLM was used by 24% of patients with no CAD, 51% of patients with nonobstructive CAD, 72% of patients with obstructive CAD on CTA without myocardial ischemia, and 91% of patients with myocardial ischemia. The use of LLM decreased during follow-up, with 77% of patients with myocardial ischemia using LLM for 2 years. The use of LLM was associated with a lower annual rate of adverse events in patients with myocardial ischemia (6.1% vs 2.8%; P = 0.032) or obstructive CAD without myocardial ischemia (2.9% vs 1.4%; P = 0.004) but not in patients with nonobstructive CAD (1.5% vs 1.4%; P = 0.89) or no CAD (0.3% vs 0.3%; P = 0.68).

Conclusions

The CAD phenotype defined by anatomical and functional imaging guides the use of LLM. The presence of myocardial ischemia and anatomical obstructive coronary lesions were associated with a long-term outcome benefit from LLM.

背景：解剖和功能成像可识别冠状动脉疾病（CAD）的不同表型，这可能会对降脂药物（LLM）产生影响：本研究旨在评估疑似阻塞性冠状动脉疾病患者在进行联合解剖和功能成像后，降脂药物与长期预后之间的关联：连续性患者（n = 1,973；41%为男性；中位年龄：63岁）因怀疑患有CAD而接受冠状动脉计算机断层扫描血管造影术（CTA）。CTA 未排除阻塞性 CAD 的患者接受了正电子发射断层扫描缺血测试。收集患者购买 LLM 的数据直至 2 年，并在中位 6.7 年时评估死亡、心肌梗死和不稳定型心绞痛的综合终点：成像后，24% 的无 CAD 患者、51% 的非阻塞性 CAD 患者、72% 的 CTA 检查无心肌缺血的阻塞性 CAD 患者和 91% 的心肌缺血患者使用了 LLM。随访期间，LLM 的使用率有所下降，77% 的心肌缺血患者使用 LLM 达 2 年之久。在心肌缺血患者（6.1% vs 2.8%；P = 0.032）或无心肌缺血的阻塞性CAD患者（2.9% vs 1.4%；P = 0.004）中，使用LLM与较低的不良事件年发生率相关，但在无阻塞性CAD患者（1.5% vs 1.4%；P = 0.89）或无CAD患者（0.3% vs 0.3%；P = 0.68）中则不相关：由解剖和功能成像确定的 CAD 表型为 LLM 的使用提供了指导。心肌缺血和解剖阻塞性冠状动脉病变的存在与 LLM 的长期疗效相关。

{"title":"Lipid-Lowering Medication and Outcomes After Anatomical and Functional Imaging in Suspected Coronary Artery Disease","authors":"Teemu Maaniitty MD, PhD , Matias Mäenpää MD , Esa Harjulahti MD , Iida Kujala MD, PhD , Iida Stenström MD, PhD , Wail Nammas MD, PhD , Juhani Knuuti MD, PhD , Antti Saraste MD, PhD","doi":"10.1016/j.jcmg.2024.07.009","DOIUrl":"10.1016/j.jcmg.2024.07.009","url":null,"abstract":"<div><h3>Background</h3><div>Anatomical and functional imaging identify different phenotypes of coronary artery disease (CAD) that may have implications for lipid-lowering medication (LLM).</div></div><div><h3>Objectives</h3><div>The aim of this study was to assess the associations between LLM and long-term outcomes after combined anatomical and functional imaging in patients with suspected obstructive CAD.</div></div><div><h3>Methods</h3><div>Consecutive patients (n = 1,973; 41% men; median age: 63 years) underwent coronary computed tomography angiography (CTA) because of suspected CAD. Patients in whom obstructive CAD was not ruled out by CTA underwent ischemia testing by positron emission tomography. Data on LLM purchases were collected until 2 years, and the combined endpoints of death, myocardial infarction, and unstable angina pectoris were assessed at a median of 6.7 years.</div></div><div><h3>Results</h3><div>After imaging, LLM was used by 24% of patients with no CAD, 51% of patients with nonobstructive CAD, 72% of patients with obstructive CAD on CTA without myocardial ischemia, and 91% of patients with myocardial ischemia. The use of LLM decreased during follow-up, with 77% of patients with myocardial ischemia using LLM for 2 years. The use of LLM was associated with a lower annual rate of adverse events in patients with myocardial ischemia (6.1% vs 2.8%; <em>P =</em> 0.032) or obstructive CAD without myocardial ischemia (2.9% vs 1.4%; <em>P =</em> 0.004) but not in patients with nonobstructive CAD (1.5% vs 1.4%; <em>P =</em> 0.89) or no CAD (0.3% vs 0.3%; <em>P =</em> 0.68).</div></div><div><h3>Conclusions</h3><div>The CAD phenotype defined by anatomical and functional imaging guides the use of LLM. The presence of myocardial ischemia and anatomical obstructive coronary lesions were associated with a long-term outcome benefit from LLM.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 1","pages":"Pages 62-73"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial Functional Mitral Regurgitation Subtypes Undergoing Transcatheter Edge-to-Edge Repair 接受经导管边缘到边缘修复术的房室功能性二尖瓣反流亚型：寰枢椎畸形的次优结果。

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.06.019

Philipp von Stein MD , Jennifer von Stein MD , Christopher Hohmann MD , Hendrik Wienemann MD , Henning Guthoff MD , Maria I. Körber MD , Stephan Baldus MD , Roman Pfister MD , Rebecca T. Hahn MD , Christos Iliadis MD

Background

Two subtypes of atrial functional mitral regurgitation (AFMR) have been described, one is characterized by Carpentier type I and the other by Carpentier type IIIb leaflet motion.

Objectives

The authors sought to analyze echocardiographic characteristics and outcomes of AFMR subtypes undergoing mitral valve transcatheter edge-to-edge repair (M-TEER).

Methods

Of 1,047 consecutive patients who underwent M-TEER, the authors identified those with isolated mitral annulus dilation (Carpentier I), termed AFMR-IAD, and those with atriogenic hamstringing characterized by restricted posterior mitral leaflet motion (Carpentier IIIb), termed AFMR-AH. Echocardiographic baseline characteristics and outcomes up to 1-year were analyzed.

Results

A total of 128 patients (12.2%) met AFMR criteria; 75 (58.6%) were identified as AFMR-IAD and 53 (41.4%) as AFMR-AH. AFMR-AH displayed greater left atrial and left ventricular volumes, greater mitral annulus, shorter and steeper posterior mitral leaflet, and more pronounced MR (all P < 0.05). Technical success was achieved in 98.7% (AFMR-IAD) and 86.8% (AFMR-AH) of patients (P = 0.009). At discharge, device detachments were exclusively observed in AFMR-AH (10.0%). MR ≤II was achieved in 95.6% and 78.6% at 30 days (P = 0.009) and in 93.0% and 74.1% at 1 year (P = 0.038) in patients with AFMR-IAD and AFMR-AH, respectively. AFMR-AH was associated with procedural failure (OR: 1.17 [95% CI: 1.00-1.38]; P = 0.045) at 30 days (43.4% vs 24.0%; P = 0.023) and all-cause mortality (HR: 2.54 [95% CI: 1.09-5.91]; P = 0.031) at 1 year (77% vs 92%, Kaplan-Meier estimated 1-year survival; P = 0.017).

Conclusions

AFMR-AH shows worse procedural and clinical outcomes following M-TEER than AFMR-IAD. Thus, vigilance regarding this pathology is warranted and alternative mitral valve therapies might need to be considered.

背景：心房功能性二尖瓣反流（AFMR）有两种亚型，一种以卡彭蒂耶I型为特征，另一种以卡彭蒂耶IIIb型瓣叶运动为特征：作者试图分析接受二尖瓣经导管边缘到边缘修补术（M-TEER）的AFMR亚型的超声心动图特征和预后：在接受 M-TEER 的 1047 名连续患者中，作者确定了孤立性二尖瓣环扩张（Carpentier I）患者（称为 AFMR-IAD）和以二尖瓣后叶运动受限（Carpentier IIIb）为特征的寰枢肌束缚（atriogenic hamstringing）患者（称为 AFMR-AH）。分析了超声心动图基线特征和一年内的结果：共有128名患者（12.2%）符合AFMR标准，其中75人（58.6%）被确定为AFMR-IAD，53人（41.4%）被确定为AFMR-AH。AFMR-AH 显示出更大的左心房和左心室容积、更大的二尖瓣环、更短更陡的二尖瓣后叶以及更明显的 MR（所有 P < 0.05）。98.7%（AFMR-IAD）和86.8%（AFMR-AH）的患者获得了技术成功（P = 0.009）。出院时，仅在 AFMR-AH 中观察到装置脱落（10.0%）。AFMR-IAD和AFMR-AH患者中，分别有95.6%和78.6%的患者在30天（P = 0.009）和1年（P = 0.038）时达到MR≤II，分别为93.0%和74.1%。AFMR-AH与30天后的手术失败（OR：1.17 [95% CI：1.00-1.38]；P = 0.045）（43.4% vs 24.0%；P = 0.023）和1年后的全因死亡率（HR：2.54 [95% CI：1.09-5.91]；P = 0.031）（77% vs 92%，Kaplan-Meier估计的1年生存率；P = 0.017）有关：结论：与 AFMR-IAD 相比，AFMR-AH 在 M-TEER 后显示出更差的手术和临床结果。结论：与AFMR-IAD相比，AFMR-AH在M-TEER术后的手术和临床预后更差，因此需要警惕这种病变，并考虑采用其他二尖瓣疗法。

{"title":"Atrial Functional Mitral Regurgitation Subtypes Undergoing Transcatheter Edge-to-Edge Repair","authors":"Philipp von Stein MD , Jennifer von Stein MD , Christopher Hohmann MD , Hendrik Wienemann MD , Henning Guthoff MD , Maria I. Körber MD , Stephan Baldus MD , Roman Pfister MD , Rebecca T. Hahn MD , Christos Iliadis MD","doi":"10.1016/j.jcmg.2024.06.019","DOIUrl":"10.1016/j.jcmg.2024.06.019","url":null,"abstract":"<div><h3>Background</h3><div>Two subtypes of atrial functional mitral regurgitation (AFMR) have been described, one is characterized by Carpentier type I and the other by Carpentier type IIIb leaflet motion.</div></div><div><h3>Objectives</h3><div>The authors sought to analyze echocardiographic characteristics and outcomes of AFMR subtypes undergoing mitral valve transcatheter edge-to-edge repair (M-TEER).</div></div><div><h3>Methods</h3><div>Of 1,047 consecutive patients who underwent M-TEER, the authors identified those with isolated mitral annulus dilation (Carpentier I), termed AFMR-IAD, and those with atriogenic hamstringing characterized by restricted posterior mitral leaflet motion (Carpentier IIIb), termed AFMR-AH. Echocardiographic baseline characteristics and outcomes up to 1-year were analyzed.</div></div><div><h3>Results</h3><div>A total of 128 patients (12.2%) met AFMR criteria; 75 (58.6%) were identified as AFMR-IAD and 53 (41.4%) as AFMR-AH. AFMR-AH displayed greater left atrial and left ventricular volumes, greater mitral annulus, shorter and steeper posterior mitral leaflet, and more pronounced MR (all <em>P <</em> 0.05). Technical success was achieved in 98.7% (AFMR-IAD) and 86.8% (AFMR-AH) of patients (<em>P =</em> 0.009). At discharge, device detachments were exclusively observed in AFMR-AH (10.0%). MR ≤II was achieved in 95.6% and 78.6% at 30 days (<em>P</em> = 0.009) and in 93.0% and 74.1% at 1 year (<em>P =</em> 0.038) in patients with AFMR-IAD and AFMR-AH, respectively. AFMR-AH was associated with procedural failure (OR: 1.17 [95% CI: 1.00-1.38]; <em>P =</em> 0.045) at 30 days (43.4% vs 24.0%; <em>P =</em> 0.023) and all-cause mortality (HR: 2.54 [95% CI: 1.09-5.91]; <em>P =</em> 0.031) at 1 year (77% vs 92%, Kaplan-Meier estimated 1-year survival; <em>P =</em> 0.017).</div></div><div><h3>Conclusions</h3><div>AFMR-AH shows worse procedural and clinical outcomes following M-TEER than AFMR-IAD. Thus, vigilance regarding this pathology is warranted and alternative mitral valve therapies might need to be considered.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 1","pages":"Pages 16-29"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Strategy of Atrial Functional Mitral Regurgitation 心房功能性二尖瓣反流的治疗策略：考虑机制亚型。

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.07.027

Nobuyuki Kagiyama MD, PhD

引用次数: 0

Structural Heart Imaging Using 3-Dimensional Intracardiac Echocardiography 使用三维心内超声心动图进行心脏结构成像：JACC 影像学立场声明

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.05.012

Gilbert H.L. Tang MD, MSc, MBA , Syed Zaid MD , Rebecca T. Hahn MD , Vratika Aggarwal MD , Mohamad Alkhouli MD , Edris Aman MD , Sergio Berti MD , Y.S. Chandrashekhar MD, DM , Scott M. Chadderdon MD , Andreina D’Agostino MD , Neil P. Fam MD , Edwin C. Ho MD , Chad Kliger MD , Susheel K. Kodali MD , Parasuram Krishnamoorthy MD , Azeem Latib MD , Stamatios Lerakis MD, PhD , D. Scott Lim MD , Vaikom S. Mahadevan MD , Devi G. Nair MD , Ralph Stephan von Bardeleben MD

3-dimensional (3D) intracardiac echocardiography (ICE) is emerging as a promising complement and potential alternative to transesophageal echocardiography for imaging guidance in structural heart interventions. To establish standardized practices, our multidisciplinary expert position statement serves as a comprehensive guide for the appropriate indications and utilization of 3D-ICE in various structural heart procedures. The paper covers essential aspects such as the fundamentals of 3D-ICE imaging, basic views, and workflow recommendations specifically tailored for ICE-guided structural heart procedures, such as transeptal puncture, device closure of intracardiac structures, and transcatheter mitral and tricuspid valve interventions. Current challenges, future directions, and training requirements to ensure operator proficiency are also discussed, thereby promoting the safety and efficacy of this innovative imaging modality to support expanding its future clinical applications.

三维（3D）心腔内超声心动图（ICE）正在成为经食道超声心动图在结构性心脏介入成像指导方面的一种有前途的补充和潜在替代方法。为了建立标准化的操作规范，我们的多学科专家立场声明为各种结构性心脏手术中 3D-ICE 的适当适应症和使用提供了全面指导。本文涵盖了一些重要方面，如三维成像的基本原理、基本视图，以及专门针对 ICE 引导的结构性心脏手术（如经瓣膜穿刺、心内结构的装置闭合、经导管二尖瓣和三尖瓣介入）的工作流程建议。此外，还讨论了当前的挑战、未来的方向和培训要求，以确保操作人员的熟练程度，从而提高这种创新成像模式的安全性和有效性，支持扩大其未来的临床应用。

{"title":"Structural Heart Imaging Using 3-Dimensional Intracardiac Echocardiography","authors":"Gilbert H.L. Tang MD, MSc, MBA , Syed Zaid MD , Rebecca T. Hahn MD , Vratika Aggarwal MD , Mohamad Alkhouli MD , Edris Aman MD , Sergio Berti MD , Y.S. Chandrashekhar MD, DM , Scott M. Chadderdon MD , Andreina D’Agostino MD , Neil P. Fam MD , Edwin C. Ho MD , Chad Kliger MD , Susheel K. Kodali MD , Parasuram Krishnamoorthy MD , Azeem Latib MD , Stamatios Lerakis MD, PhD , D. Scott Lim MD , Vaikom S. Mahadevan MD , Devi G. Nair MD , Ralph Stephan von Bardeleben MD","doi":"10.1016/j.jcmg.2024.05.012","DOIUrl":"10.1016/j.jcmg.2024.05.012","url":null,"abstract":"<div><div><span>3-dimensional (3D) intracardiac echocardiography (ICE) is emerging as a promising complement and potential alternative to </span>transesophageal echocardiography<span> for imaging guidance in structural heart interventions. To establish standardized practices, our multidisciplinary expert position statement serves as a comprehensive guide for the appropriate indications and utilization of 3D-ICE in various structural heart procedures. The paper covers essential aspects such as the fundamentals of 3D-ICE imaging, basic views, and workflow recommendations specifically tailored for ICE-guided structural heart procedures, such as transeptal puncture, device closure of intracardiac structures, and transcatheter mitral and tricuspid valve interventions. Current challenges, future directions, and training requirements to ensure operator proficiency are also discussed, thereby promoting the safety and efficacy of this innovative imaging modality to support expanding its future clinical applications.</span></div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 1","pages":"Pages 93-115"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing Medical Therapy Following Cardiac Imaging 优化心脏成像后的医学治疗：是时候提升我们的游戏了？

IF 12.8 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC. Cardiovascular imaging

Pub Date : 2025-01-01 DOI: 10.1016/j.jcmg.2024.10.003

Ron Blankstein MD, Siddharth J. Trivedi MBBS, PhD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JACC. Cardiovascular imaging

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀